Cover Image
Market Research Report

Male Health Drug Development Pipeline Review, 2017

Published by GlobalData Product code 564939
Published Content info 125 Pages
Delivery time: 1-2 business days
Price
Back to Top
Male Health Drug Development Pipeline Review, 2017
Published: September 25, 2017 Content info: 125 Pages
Description

Executive Summary:

Male hypogonadism is characterized by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). There are a total of 23 products in development for this indication, by 19 companies and one academic institution. Key companies operating in this pipeline space include Lipocine, M et P Pharma, Repros Therapeutics and TesoRx Pharma.

Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient to permit satisfactory intercourse. There are a total of 36 products in development for this indication, by 31 companies and two academic institutions. Key companies operating in this pipeline space include Mitsubishi Tanabe Pharma, Futura Medical, Monosol Rx and NAL Pharmaceuticals.

Finally, Benign prostatic hyperplasia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 29 products in development for this indication, by 26 companies and four academic institutions. Key companies operating in this pipeline space include Chong Kun Dang Pharmaceutical, Nymox Pharmaceutical and Yungjin Pharm.

The most common target for male hypogonadism is the androgen receptor, while phosphodiesterase 5 targets dominate the erectile dysfunction pipeline. Targets for the treatment of benign prostatic hyperplasia are more diverse with a strong presence of both androgen receptor and phosphodiesterase targets.

The report, "Male Health Drug Development Pipeline Review, 2017" provides an overview of the male health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Scope:

  • Which companies are the most active within the pipeline for male health therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of male health?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
Product Code: GBIHC020IDB

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Male Health Report Coverage
  • 2.2. Male Hypogonadism. Overview
  • 2.3. Erectile Dysfunction. Overview
  • 2.4. Benign Prostatic Hyperplasia. Overview

3. Therapeutics Development

  • 3.1. Male Hypogonadism
  • 3.2. Erectile Dysfunction
  • 3.3. Benign Prostatic Hyperplasia

4. Therapeutics Assessment

  • 4.1. Male Hypogonadism
  • 4.2. Erectile Dysfunction
  • 4.3. Benign Prostatic Hyperplasia

5. Companies Involved in Therapeutics Development

  • 5.1. Male Hypogonadism
  • 5.2. Erectile Dysfunction
  • 5.3. Benign Prostatic Hyperplasia

6. Dormant Projects

  • 6.1. Male Hypogonadism
  • 6.2. Erectile Dysfunction
  • 6.3. Benign Prostatic Hyperplasia

7. Discontinued Products

  • 7.1. Male Hypogonadism
  • 7.2. Erectile Dysfunction
  • 7.3. Benign Prostatic Hyperplasia

8. Product Development Milestones

  • 8.1. Male Hypogonadism
  • 8.2. Erectile Dysfunction
  • 8.3. Benign Prostatic Hyperplasia

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Male Hypogonadism, H2 2017
  • Table 2: Number of Products under Development by Companies, H2 2017
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2017
  • Table 4: Products under Development by Companies, H2 2017
  • Table 5: Products under Development by Universities/Institutes, H2 2017
  • Table 6: Number of Products under Development for Erectile Dysfunction, H2 2017
  • Table 7: Number of Products under Development by Companies, H2 2017
  • Table 8: Number of Products under Development by Universities/Institutes, H2 2017
  • Table 9: Products under Development by Companies, H2 2017
  • Table 10: Products under Development by Universities/Institutes, H2 2017
  • Table 11: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
  • Table 12: Number of Products under Development by Companies, H2 2017
  • Table 13: Number of Products under Development by Universities/Institutes, H2 2017
  • Table 14: Products under Development by Companies, H2 2017
  • Table 15: Products under Development by Universities/Institutes, H2 2017
  • Table 16: Number of Products by Stage and Target, H2 2017
  • Table 17: Number of Products by Stage and Mechanism of Action, H2 2017
  • Table 18: Number of Products by Stage and Route of Administration, H2 2017
  • Table 19: Number of Products by Stage and Molecule Type, H2 2017
  • Table 20: Number of Products by Stage and Target, H2 2017
  • Table 21: Number of Products by Stage and Mechanism of Action, H2 2017
  • Table 22: Number of Products by Stage and Route of Administration, H2 2017
  • Table 23: Number of Products by Stage and Molecule Type, H2 2017
  • Table 24: Number of Products by Stage and Target, H2 2017
  • Table 25: Number of Products by Stage and Mechanism of Action, H2 2017
  • Table 26: Number of Products by Stage and Route of Administration, H2 2017
  • Table 27: Number of Products by Stage and Molecule Type, H2 2017
  • Table 28: Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2017
  • Table 29: Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2017
  • Table 30: Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2017
  • Table 31: Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2017
  • Table 32: Male Hypogonadism - Pipeline by Lipocine Inc, H2 2017
  • Table 33: Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2017
  • Table 34: Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2017
  • Table 35: Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2017
  • Table 36: Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2017
  • Table 37: Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2017
  • Table 38: Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2017
  • Table 39: Male Hypogonadism - Pipeline by The Female Health Company, H2 2017
  • Table 40: Male Hypogonadism - Pipeline by Viramal Ltd, H2 2017
  • Table 41: Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2017
  • Table 42: Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2017
  • Table 43: Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2017
  • Table 44: Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2017
  • Table 45: Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2017
  • Table 46: Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
  • Table 47: Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2017
  • Table 48: Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Table 49: Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2017
  • Table 50: Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2017
  • Table 51: Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2017
  • Table 52: Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H2 2017
  • Table 53: Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2017
  • Table 54: Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Table 55: Erectile Dysfunction - Pipeline by Monosol Rx LLC, H2 2017
  • Table 56: Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2017
  • Table 57: Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
  • Table 58: Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017
  • Table 59: Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017
  • Table 60: Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2017
  • Table 61: Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2017
  • Table 62: Erectile Dysfunction - Pipeline by Suda Ltd, H2 2017
  • Table 63: Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
  • Table 64: Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2017
  • Table 65: Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H2 2017
  • Table 66: Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Table 67: Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H2 2017
  • Table 68: Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2017
  • Table 69: Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2017
  • Table 70: Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2017
  • Table 71: Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Table 72: Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2017
  • Table 73: Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017
  • Table 74: Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H2 2017
  • Table 75: Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017
  • Table 76: Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Table 77: Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H2 2017
  • Table 78: Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
  • Table 79: Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2017
  • Table 80: Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2017
  • Table 81: Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Table 82: Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H2 2017
  • Table 83: Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H2 2017
  • Table 84: Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2017
  • Table 85: Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Table 86: Benign Prostatic Hyperplasia - Pipeline by The Female Health Company, H2 2017
  • Table 87: Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
  • Table 88: Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H2 2017
  • Table 89: Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2017
  • Table 90: Male Hypogonadism - Dormant Projects, H2 2017
  • Table 91: Erectile Dysfunction - Dormant Projects, H2 2017
  • Table 92: Benign Prostatic Hyperplasia - Dormant Projects, H2 2017
  • Table 93: Male Hypogonadism - Discontinued Products, H2 2017
  • Table 94: Erectile Dysfunction - Discontinued Products, H2 2017
  • Table 95: Benign Prostatic Hyperplasia - Discontinued Products, H2 2017

List of Figures

  • Figure 1: Number of Products under Development for Male Hypogonadism, H2 2017
  • Figure 2: Number of Products under Development by Companies, H2 2017
  • Figure 3: Number of Products under Development for Erectile Dysfunction, H2 2017
  • Figure 4: Number of Products under Development by Companies, H2 2017
  • Figure 5: Number of Products under Development by Universities/Institutes, H2 2017
  • Figure 6: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
  • Figure 7: Number of Products under Development by Companies, H2 2017
  • Figure 8: Number of Products under Development by Universities/Institutes, H2 2017
  • Figure 9: Number of Products by Targets, H2 2017
  • Figure 10: Number of Products by Stage and Targets, H2 2017
  • Figure 11: Number of Products by Mechanism of Actions, H2 2017
  • Figure 12: Number of Products by Stage and Mechanism of Actions, H2 2017
  • Figure 13: Number of Products by Routes of Administration, H2 2017
  • Figure 14: Number of Products by Stage and Routes of Administration, H2 2017
  • Figure 15: Number of Products by Molecule Types, H2 2017
  • Figure 16: Number of Products by Stage and Molecule Types, H2 2017
  • Figure 17: Number of Products by Top 10 Targets, H2 2017
  • Figure 18: Number of Products by Stage and Top 10 Targets, H2 2017
  • Figure 19: Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Figure 21: Number of Products by Routes of Administration, H2 2017
  • Figure 22: Number of Products by Stage and Routes of Administration, H2 2017
  • Figure 23: Number of Products by Molecule Types, H2 2017
  • Figure 24: Number of Products by Stage and Molecule Types, H2 2017
  • Figure 25: Number of Products by Top 10 Targets, H2 2017
  • Figure 26: Number of Products by Stage and Top 10 Targets, H2 2017
  • Figure 27: Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Figure 29: Number of Products by Routes of Administration, H2 2017
  • Figure 30: Number of Products by Stage and Routes of Administration, H2 2017
  • Figure 31: Number of Products by Molecule Types, H2 2017
  • Figure 32: Number of Products by Stage and Molecule Types, H2 2017
Back to Top